Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 0

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 0
---
Item 3. Key Information

  [Reserved.]  
 ───────────────

  Capitalization and Indebtedness  
 ───────────────────────────────────

Not applicable.

  Reasons for the Offer and Use of Proceeds  
 ─────────────────────────────────────────────

Not applicable.

  Risk Factors  
 ────────────────

You should carefully consider
the risks described below before making an investment decision. Our business, financial condition or results of operations could be materially
and adversely affected by any of these risks. The trading price and value of our ordinary shares could decline due to any of these risks,
and you may lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties.
Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors,
including the risks faced by us described below and elsewhere in this Annual Report. See “ Cautionary Statement Regarding Forward-Looking
Statements” on page iv of this Annual Report. Such risks include, but are not limited to:

Risks Related to Our Financial Condition and
Capital Requirements

We have incurred significant losses since
inception and have not generated any revenue to date. We expect to incur losses over the next several years and may not be able to achieve
or sustain revenues or profitability in the future.

Investment in the medical
device industry and product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant
risk that our Alpha DaRT technology will fail to demonstrate adequate efficacy or an acceptable safety profile, gain marketing authorization
in the United States and similar authorization or certification in various other jurisdictions worldwide and become commercially viable.
We currently have no products authorized for commercial sale in the United States and have not generated any revenue to date, and we continue
to incur significant research and development and other expenses related to our ongoing operations. To date, we have financed our operations
primarily through private placements of our ordinary and preferred shares as well as through grants received from government authorities,
primarily in Israel.

We have incurred significant
net losses in each period since we commenced activity in 2016. Our net losses were $29,157 and $31,750 for the years ended December 31,
2023 and December 31, 2024, respectively. As of December 31, 2024, we had an accumulated deficit of $147,509. We expect to continue to
incur significant losses for the foreseeable future, and we expect